QQQ   303.60 (+0.00%)
AAPL   152.35 (+0.41%)
MSFT   262.76 (+2.33%)
META   186.02 (-0.02%)
GOOGL   103.75 (+0.83%)
AMZN   100.50 (-1.64%)
TSLA   195.85 (+0.56%)
NVDA   212.85 (+0.93%)
NIO   10.90 (-0.27%)
BABA   105.89 (+0.42%)
AMD   83.97 (+0.35%)
T   19.45 (-0.66%)
F   13.11 (-0.23%)
MU   60.12 (+0.23%)
CGC   2.89 (-2.03%)
GE   81.57 (-0.95%)
DIS   109.70 (-0.15%)
AMC   6.64 (-2.35%)
PFE   43.85 (+0.21%)
PYPL   81.89 (-0.53%)
NFLX   357.85 (-1.00%)
QQQ   303.60 (+0.00%)
AAPL   152.35 (+0.41%)
MSFT   262.76 (+2.33%)
META   186.02 (-0.02%)
GOOGL   103.75 (+0.83%)
AMZN   100.50 (-1.64%)
TSLA   195.85 (+0.56%)
NVDA   212.85 (+0.93%)
NIO   10.90 (-0.27%)
BABA   105.89 (+0.42%)
AMD   83.97 (+0.35%)
T   19.45 (-0.66%)
F   13.11 (-0.23%)
MU   60.12 (+0.23%)
CGC   2.89 (-2.03%)
GE   81.57 (-0.95%)
DIS   109.70 (-0.15%)
AMC   6.64 (-2.35%)
PFE   43.85 (+0.21%)
PYPL   81.89 (-0.53%)
NFLX   357.85 (-1.00%)
QQQ   303.60 (+0.00%)
AAPL   152.35 (+0.41%)
MSFT   262.76 (+2.33%)
META   186.02 (-0.02%)
GOOGL   103.75 (+0.83%)
AMZN   100.50 (-1.64%)
TSLA   195.85 (+0.56%)
NVDA   212.85 (+0.93%)
NIO   10.90 (-0.27%)
BABA   105.89 (+0.42%)
AMD   83.97 (+0.35%)
T   19.45 (-0.66%)
F   13.11 (-0.23%)
MU   60.12 (+0.23%)
CGC   2.89 (-2.03%)
GE   81.57 (-0.95%)
DIS   109.70 (-0.15%)
AMC   6.64 (-2.35%)
PFE   43.85 (+0.21%)
PYPL   81.89 (-0.53%)
NFLX   357.85 (-1.00%)
QQQ   303.60 (+0.00%)
AAPL   152.35 (+0.41%)
MSFT   262.76 (+2.33%)
META   186.02 (-0.02%)
GOOGL   103.75 (+0.83%)
AMZN   100.50 (-1.64%)
TSLA   195.85 (+0.56%)
NVDA   212.85 (+0.93%)
NIO   10.90 (-0.27%)
BABA   105.89 (+0.42%)
AMD   83.97 (+0.35%)
T   19.45 (-0.66%)
F   13.11 (-0.23%)
MU   60.12 (+0.23%)
CGC   2.89 (-2.03%)
GE   81.57 (-0.95%)
DIS   109.70 (-0.15%)
AMC   6.64 (-2.35%)
PFE   43.85 (+0.21%)
PYPL   81.89 (-0.53%)
NFLX   357.85 (-1.00%)
NASDAQ:ATRA

Atara Biotherapeutics - ATRA Stock Forecast, Price & News

$5.52
+0.12 (+2.22%)
(As of 02/7/2023 09:38 AM ET)
Add
Compare
Today's Range
$5.40
▼
$5.55
50-Day Range
$2.85
▼
$5.46
52-Week Range
$2.83
▼
$16.07
Volume
62,080 shs
Average Volume
1.02 million shs
Market Capitalization
$523.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.63

Atara Biotherapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
261.1% Upside
$19.50 Price Target
Short Interest
Bearish
14.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.02mentions of Atara Biotherapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$133,802 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.05) to ($2.44) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

739th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

122nd out of 169 stocks

See Top Rated MarketRank™ Stocks Here
ATRA stock logo

About Atara Biotherapeutics (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRA Stock News Headlines

February 7, 2023 | americanbankingnews.com
Atara Biotherapeutics (ATRA) Set to Announce Quarterly Earnings on Wednesday
February 6, 2023 | finance.yahoo.com
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
February 7, 2023 | Investing Trends (Ad)
Apple, Amazon, and Walmart are Investing in Solar Energy
The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
January 28, 2023 | americanbankingnews.com
Brokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) PT at $19.50
January 4, 2023 | finance.yahoo.com
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 4, 2023 | finance.yahoo.com
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 | marketwatch.com
Atara Biotherapeutics Gets $31M Royalty Interest Financing Deal, Shares Rise 6%
December 20, 2022 | finance.yahoo.com
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
February 7, 2023 | Investing Trends (Ad)
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
December 19, 2022 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Madrigal Pharmaceuticals (MDGL) and Atara Biotherapeutics (ATRA)
December 19, 2022 | benzinga.com
Atara Biotherapeutics' Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
December 19, 2022 | markets.businessinsider.com
Atara's Ebvallo Receives European Commission Approval For Adults And Children With EBV+ PTLD
December 19, 2022 | finance.yahoo.com
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
December 19, 2022 | finance.yahoo.com
Atara Biotherapeutics Announces Changes to Its Board of Directors
December 17, 2022 | seekingalpha.com
Consider Atara Biotherapeutics As The Tab-Cel Delay Resolves In The U.S.
December 12, 2022 | finance.yahoo.com
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
November 23, 2022 | finance.yahoo.com
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
November 22, 2022 | finance.yahoo.com
Newsflash: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Have Been Trimming Their Revenue Forecasts
November 10, 2022 | finance.yahoo.com
Atara Biotherapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In Line
November 9, 2022 | finance.yahoo.com
Atara Biotherapeutics to Participate at the Stifel Healthcare Conference
November 8, 2022 | markets.businessinsider.com
Mizuho Securities Keeps Their Buy Rating on Atara Biotherapeutics (ATRA)
November 8, 2022 | finance.yahoo.com
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
November 7, 2022 | msn.com
Atara Biotherapeutics's Earnings: A Preview
November 1, 2022 | finance.yahoo.com
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 26, 2022 | finance.yahoo.com
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
October 14, 2022 | finance.yahoo.com
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
October 10, 2022 | finance.yahoo.com
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
See More Headlines
Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRA Company Calendar

Last Earnings
11/04/2021
Today
2/07/2023
Next Earnings (Confirmed)
2/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATRA
CUSIP
N/A
CIK
1604464
Web
www.atarabio.com
Phone
(650) 278-8930
Fax
N/A
Employees
578
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.50
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+291.8%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-340,140,000.00
Net Margins
-348.49%
Pretax Margin
-348.43%
Return on Equity
-125.38%
Return on Assets
-71.22%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.92
Quick Ratio
3.92

Sales & Book Value

Annual Sales
$20.34 million
Price / Sales
25.75
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.16 per share
Price / Book
1.75

Miscellaneous

Outstanding Shares
94,880,000
Free Float
91,084,000
Market Cap
$523.74 million
Optionable
Optionable
Beta
0.94

Key Executives

  • Pascal TouchonPascal Touchon
    President, Chief Executive Officer & Director
  • Utpal KoppikarUtpal Koppikar
    Chief Financial Officer & Senior Vice President
  • Manher AJ Joshi
    Chief Medical Officer
  • Jakob DupontJakob Dupont
    Global Head-Research & Development
  • Anhco Nguyen
    Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ATRA Stock - Frequently Asked Questions

Should I buy or sell Atara Biotherapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares.
View ATRA analyst ratings or view top-rated stocks.

What is Atara Biotherapeutics' stock price forecast for 2023?

7 analysts have issued 1 year target prices for Atara Biotherapeutics' stock. Their ATRA share price forecasts range from $3.00 to $50.00. On average, they expect the company's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 261.1% from the stock's current price.
View analysts price targets for ATRA or view top-rated stocks among Wall Street analysts.

How have ATRA shares performed in 2023?

Atara Biotherapeutics' stock was trading at $3.28 on January 1st, 2023. Since then, ATRA stock has increased by 64.6% and is now trading at $5.40.
View the best growth stocks for 2023 here.

When is Atara Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ATRA earnings forecast.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) issued its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.02. The biotechnology company earned $5.37 million during the quarter, compared to analyst estimates of $5.31 million. Atara Biotherapeutics had a negative trailing twelve-month return on equity of 125.38% and a negative net margin of 348.49%. During the same quarter last year, the business posted ($0.92) earnings per share.

What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.44%), Pinnacle Associates Ltd. (0.41%), Hennion & Walsh Asset Management Inc. (0.29%), Allspring Global Investments Holdings LLC (0.05%), SG Americas Securities LLC (0.03%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Insiders that own company stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $5.40.

How much money does Atara Biotherapeutics make?

Atara Biotherapeutics (NASDAQ:ATRA) has a market capitalization of $512.35 million and generates $20.34 million in revenue each year. The biotechnology company earns $-340,140,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Atara Biotherapeutics have?

The company employs 578 workers across the globe.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.atarabio.com. The biotechnology company can be reached via phone at (650) 278-8930 or via email at ehyllengren@atarabio.com.

This page (NASDAQ:ATRA) was last updated on 2/7/2023 by MarketBeat.com Staff